ESMO精准肿瘤学工作组关于临床实践中分子肿瘤委员会结构与质量指标的推荐
ESMO精准肿瘤学工作组(POWG)通过国际专家小组多次咨询与共识流程,为分子肿瘤委员会(MTB)的结构与质量指标制定推荐。共识定义了MTB流程的五个关键组成部分,并提出质量指标,包括病例讨论周转时间及可操作推荐与临床试验入组成功实施的比例,以促进精准肿瘤学的标准化整合。
要点
- MTB主要任务是为复杂基因组变异病例提供基因组信息指导的临床推荐。
- MTB应包含跨学科专业知识,关键角色为具备基因组专业知识的肿瘤科医生、接受分子培训的病理学家和临床遗传学家。
- MTB推荐应记录于结构化报告,包含基因组指导的治疗策略、潜在肿瘤检测到的胚系变异管理计划及额外基因组检测指导。
核心结论
- ESMO POWG的这些推荐可作为指南,帮助定义MTB的质量标准,以促进协调并进一步加速精准肿瘤学融入临床实践。
研究设计与样本
- ESMO精准肿瘤学工作组(POWG)成立精准肿瘤学国际专家小组,确定核心关注领域。
- 经过多次咨询并通过专家共识流程,该小组就每项推荐达成共识水平。
主要发现
- 小组定义了MTB流程中对功能和临床使用至关重要的五个组成部分。
- MTB主要任务是为复杂基因组变异病例提供基因组信息指导的临床推荐。
- MTB应包含跨学科专业知识,关键角色为具备基因组专业知识的肿瘤科医生、接受分子培训的病理学家和临床遗传学家。
- MTB推荐应记录于结构化报告,包含基因组指导的治疗策略、潜在肿瘤检测到的胚系变异管理计划及额外基因组检测指导。
- 应实施结构化随访流程以监测MTB推荐的临床有效性,小组还提出了MTB运行的质量指标,包括病例讨论周转时间及可操作推荐和临床试验入组成功实施的比例。
关键数值与推荐
- MTB主要任务:为复杂基因组变异病例提供基因组信息指导的临床推荐。
- MTB组成:应包含跨学科专业知识,关键角色为具备基因组专业知识的肿瘤科医生、接受分子培训的病理学家和临床遗传学家。
- 结构化报告:应包含基因组指导的治疗策略、潜在肿瘤检测到的胚系变异管理计划及额外基因组检测指导。
- 随访流程:应实施结构化随访以监测MTB推荐的临床有效性。
- 质量指标:包括病例讨论周转时间及可操作推荐和临床试验入组成功实施的比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With an increased uptake of genomic profiling in clinical practice and the evolving complexity of diagnostic modalities, vast amounts of complex data need to be properly interpreted and integrated into an individualised care plan. To address these challenges, molecular tumour boards (MTBs) have been widely established. As of today, no international recommendations regulating the composition and workflows of MTBs have been defined. METHODS: ESMO's Precision Oncology Working Group (POWG) established an international expert panel in precision oncology and defined core areas of interest. After several consultations and through an expert consensus process, the group reached a consensus level for each recommendation. RESULTS: The group defined five components in the MTB process that are critical to its function and clinical use: (i) the primary task of MTBs consists in providing genomic-informed clinical recommendations, particularly for cases exhibiting complex genomic alterations; (ii) to achieve this, MTBs should encompass interdisciplinary expertise, with key roles for oncologists with genomic expertise, pathologists with molecular training and clinical geneticists; (iii) MTBs' recommendations should be documented in a structured report that includes genomic-informed treatment strategies, management plans for potential tumour-detected germline alterations and guidance for additional genomic testing; (iv) structured follow-up processes should be implemented for monitoring the clinical effectiveness of MTBs recommendations and (v) finally, the panel proposed quality indicators for operating MTBs, including turnaround times for cases discussion and the proportion of cases for which actionable recommendations and clinical trial enrolments were successfully implemented. CONCLUSIONS: These ESMO's POWG recommendations can serve as a guidance and help to define quality standards for MTBs to allow for harmonisation and to further expedite the integration of precision oncology into clinical practice.
引用
- Westphalen CB, Boscolo Bielo L, Aftimos P, et al. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Ann Oncol. 2025. PMID: 40194904. doi:10.1016/j.annonc.2025.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。